12A-1110916
US provisional application
Tuberous sclerosis complex is a hereditary disease caused by mutations on TSC1 or TSC2 gene, which leads to the overactivation of mTOR kinase and dysregulation of downstream signaling pathways. A majority of TSC patients manifest seizures during their lifetime. About 70% of these patients are classified as intractable epilepsy. In addition to seizures, TSC patients also have comorbid psychiatric disorders such as autism, sleeping problems, anxiety and other psychological manifestations. Our invention disclosed a new compound show efficacy on lowering the seizure threshold in Tsc2+/- mice with fewer side effects, when compared to a commonly used anti-epileptic drug, Vigabatrin. By incorporating non-invasive neuroimaging modalities, we found that J4 treatment was able to reverse the brain microstructural abnormalities and enhance the connectivity in Tsc2+/- mice. Furthermore, we found the new compound was able to extend the animal’s lifespan. The new invention provides a new alternative treatment for TSC for treating both TSC-related psychiatric disorders and epilepsy
- a new alternative treatment for TSC
- Therapeutic treatment for TSC-associated neuropsychiatric disorders (TAND)
- Therapeutic treatment for sleep disturbances in TSC
- Therapeutic treatment for epilepsy in TSC
- Therapeutic treatment for epilepsy.
Yijuang Chern, Yi-Chao Lee, You-Yin Chen, and Jim-Min Fang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

A compound for the treatment of tuberous sclerosis complex